Cover Image
市場調查報告書

Novartis AG:開發中產品分析

Novartis AG - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 256066
出版日期 內容資訊 英文 489 Pages
訂單完成後即時交付
價格
Back to Top
Novartis AG:開發中產品分析 Novartis AG - Product Pipeline Review - 2016
出版日期: 2016年03月22日 內容資訊: 英文 489 Pages
簡介

Novartis AG在國際的醫藥品企業,集中性地致力於新醫藥品解決方案的藥物研發·開發。供給著還有人·動物用的所有疾病·障礙作為對象的種類的處方藥·非專利產品。作為成為該公司的產品的對象的具體的疾病·障礙,癌症·心血管疾病·皮膚病·神經病變·眼科疾病·呼吸疾病·免疫障礙·感染疾病等能舉出(舉行)。在該公司還有預防用疫苗和OTC (一般藥)也銷售著。主要的活動地區成為美國·歐洲和其他的國? (RoW) 。

本報告提供美國的生物醫藥品企業,Novartis AG的醫藥品的研究開發的進展相關分析,與該公司的產品平台結構,及臨床實驗的整體進展,的主要開發中產品簡介與開發情形,該公司簡介調查著最新趨勢等。

目錄

Novartis AG:現狀

  • 企業概要
  • 主要資訊
  • 主要資料

研究開發(R&D)概況

  • 主要的治療領域

開發平台·檢討

  • 各開發階段的開發中產品
  • 開發中產品:單劑治療藥
  • 開發中產品:並用治療模式
  • 開發中產品:合作夥伴產品
  • 開發中產品:轉出授權產品

開發中產品的概要

  • 後期階段的開發中產品
    • 登記前產品/並用治療模式
    • 登記駁回的產品/並用治療模式
    • 第三階段產品/並用治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段產品/並用治療模式
    • 第一階段產品/並用治療模式
  • 初期階段的開發中產品
    • 臨床實驗前產品/並用治療模式
    • 藥物研發階段的產品/並用治療模式
  • 開發階段未公開的開發中產品
    • 非公開產品/並用治療模式

藥物簡介 (全170種)

  • (indacaterol maleate + glycopyrrolate)
    • 產品概要
    • 作用機制
    • 研究開發(R&D)的發展
  • (sacubitril + valsartan)
  • eltrombopag olamine
  • erismodegib
  • EXE-844
  • glycopyrrolate
  • haemophilus influenzae [serotype B] vaccine
  • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine
  • omalizumab
  • panobinostat
  • ruxolitinib phosphate
  • serelaxin
  • trametinib dimethyl sulfoxide
  • imatinib mesylate
  • pazopanib hydrochloride
  • (vildagliptin + metformin hydrochloride)
  • aliskiren fumarate
  • bimagrumab
  • buparlisib hydrochloride
  • canakinumab
  • ceritinib
  • dabrafenib mesylate
  • everolimus
  • EXE-844b
  • fingolimod hydrochloride
  • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine
  • midostaurin
  • nilotinib
  • ofatumumab
  • osilodrostat
  • oxytocin
  • pasireotide
  • pasireotide LAR
  • pradigastat sodium
  • ranibizumab
  • ribociclib
  • seasonal influenza (quadrivalent) vaccine
  • secukinumab
  • siponimod
  • zoledronic acid
  • (VAK-694 + dectrekumab)
  • aldesleukin
  • alpelisib
  • AQW-051
  • BCT-197
  • BGS-649
  • BHQ-880
  • BPS-804
  • BVS-857
  • CAD-106
  • capmatinib
  • CDZ-173
  • CFZ-533
  • cipargamin
  • CJM-112
  • dectrekumab
  • EGF-816
  • FCR-001
  • fevipiprant
  • GSK-2285921
  • HSC-835
  • infigratinib
  • influenza [strain H5N1] vaccine
  • KAF-156
  • KRP-203
  • LCL-161
  • LFF-269
  • LFG-316
  • LFX-453
  • ligelizumab
  • LIK-066
  • LJM-716
  • LMI-070
  • mavoglurant
  • MCS-110
  • NOV-3
  • octreotide acetate long acting
  • QAL-964
  • QBM-076
  • QBW-251
  • seasonal influenza (trivalent) vaccine
  • selurampanel
  • tisagenlecleucel-T
  • VAY-736
  • BPR-277
  • BZF-961
  • CFG-920
  • CGF-166
  • CLR-457
  • CSJ-148
  • FGF-401
  • HDM-201
  • LAG-525
  • lapatinib ditosylate
  • LEZ-763
  • LFA-102
  • LGK-974
  • PDR-001
  • PIM-447
  • RAF-265
  • sotrastaurin acetate
  • ABL-001
  • Cell Therapy to Target c-Met for Cancer
  • Cell Therapy to Target EGFR for Glioblastoma
  • CGM-097
  • huCART19
  • IDH-305
  • influenza [strain A/H3N2] (monovalent) vaccine
  • influenza [strain H7N9] (monovalent) vaccine
  • LEQ-506
  • LHW-090
  • LML-134
  • LOP-628
  • MesoCART
  • NOV-10
  • NOV-7
  • NOV-8
  • NOV-9
  • octreotide acetate LAR
  • PCA-062
  • QCC-374
  • TAP-311
  • Antibody to Inhibit PD-L1 for Cancer
  • Antibody to Inhibit TIM-3 for Cancer
  • AUSRM-057
  • BQS-481
  • BVB-808
  • CART-123
  • Cell Therapy Program for Cancer
  • Cell Therapy to Target 5T4 for Oncology
  • Cell Therapy to Target GD2 for Neuroblastoma
  • cosyntropin ER
  • ESK-1
  • GNFPf-5069
  • HG-78501
  • IMP-701
  • Kartogenin
  • KR-22809
  • LCZ-960
  • LGB-321
  • LQN-725
  • Monoclonal Antibody Conjugated 3 for Cancer
  • Monoclonal Antibody to Inhibit CXCR2 for Respiratory Diseases
  • NIBR-0213
  • NITD-349
  • NITD-916
  • NVPQBE-170
  • NVPTNKS-656
  • Small Molecule to Activate Nurr1 for Multiple Sclerosis
  • Small Molecule to Agonize GPR119 for Type 2 Diabetes
  • Small Molecule to Agonize GPR39 for Type 2 Diabetes
  • Small Molecule to Inhibit LRRK2 for Parkinsons Disease
  • Small Molecule to Inhibit OX2R for Insomnia
  • Small Molecules to Antagonize CSF1R for Cancer and Osteolysis
  • Small Molecules to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes
  • Small Molecules to Inhibit Pan-RAF Kinase for Oncology
  • Antibodies to Inhibit CTLA4 and PD-1 for Cancer
  • ESBA-903 SR
  • LJH-685
  • Small Molecule to Agonize Adrenergic Beta-2 Receptor for COPD
  • Small Molecules 1 for Undisclosed Indication
  • Small Molecules 2 for Undisclosed Indication
  • Small Molecules for Malaria
  • Small Molecules for Rhinovirus Infection
  • Small Molecules for Tuberculosis
  • Small Molecules to Inhibit Acetyl-CoA Carboxylase for Metabolic, Cardiovascular and Infections
  • Small Molecules to Inhibit CFTR for Secretory Diarrhea
  • Small Molecules to Inhibit PI4KIIIbeta for HCV
  • Small Molecules to Inhibit Renin for Hypertension
  • Small Molecules for Mycobacterium Tuberculosis

開發平台分析

  • 標的別
  • 各投藥法
  • 各分子類型
  • 各作用機制

開發中產品的最新趨勢

開發暫停的產品

開發中止的產品

  • 開發中止的產品簡介

企業的聲明

公司所在地及子公司

  • 總公司
  • 其他的公司所在地·子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07987CDB

Summary

Global Markets Direct's, 'Novartis AG - Product Pipeline Review - 2016', provides an overview of the Novartis AG's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Novartis AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Novartis AG
  • The report provides overview of Novartis AG including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Novartis AG's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Novartis AG's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Novartis AG's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Novartis AG
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Novartis AG's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Novartis AG Snapshot
    • Novartis AG Overview
    • Key Information
    • Key Facts
  • Novartis AG - Research and Development Overview
    • Key Therapeutic Areas
  • Novartis AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Novartis AG - Pipeline Products Glance
  • Novartis AG - Late Stage Pipeline Products
  • Novartis AG - Clinical Stage Pipeline Products
  • Novartis AG - Early Stage Pipeline Products
  • Novartis AG - Drug Profiles
    • ceritinib
    • dabrafenib mesylate + trametinib dimethyl sulfoxide
    • eltrombopag olamine
    • everolimus
    • serelaxin
    • trametinib dimethyl sulfoxide
    • zoledronic acid
    • imatinib mesylate
    • panobinostat
    • pazopanib hydrochloride
    • (glycopyrrolate + indacaterol maleate + mometasone fuorate)
    • (indacaterol maleate + mometasone furoate)
    • (sacubitril + valsartan)
    • alpelisib
    • bimagrumab
    • buparlisib hydrochloride
    • canakinumab
    • dabrafenib mesylate
    • fevipiprant
    • fingolimod hydrochloride
    • midostaurin
    • nilotinib
    • ofatumumab
    • osilodrostat phosphate
    • oxytocin
    • pasireotide
    • pasireotide ER
    • ranibizumab
    • ribociclib
    • secukinumab
    • siponimod
    • CDZ-173
    • clofazimine
    • CNP-520
    • (dectrekumab + VAK-694)
    • afuresertib hydrochloride
    • aldesleukin
    • BHQ-880
    • BVS-857
    • capmatinib
    • CFZ-533
    • cipargamin
    • CJM-112
    • dectrekumab
    • EGF-816
    • elgemtumab
    • EMA-401
    • FCR-001
    • GSK-2285921
    • HSC-835
    • iloperidone
    • infigratinib
    • KAF-156
    • KRP-203
    • LCL-161
    • LFX-453
    • LHW-090
    • ligelizumab
    • LJN-452
    • LMI-070
    • mavoglurant
    • MCS-110
    • octreotide acetate long acting
    • pradigastat sodium
    • ruxolitinib phosphate
    • selurampanel
    • sonidegib phosphate
    • tesidolumab
    • tisagenlecleucel-T
    • trametinib dimethyl sulfoxide + uprosertib
    • uprosertib
    • VAY-736
    • BZF-961
    • CGF-166
    • CSJ-137
    • CSJ-148
    • FGF-401
    • HDM-201
    • LAG-525
    • lapatinib ditosylate
    • MGB-453
    • PDR-001
    • PIM-447
    • RAF-265
    • sotrastaurin acetate
    • ABL-001
    • AV-380
    • Cellular Immunotherapy to Target c-Met for Oncology
    • Cellular Immunotherapy to Target CD22 for Acute Lymphoblastic Leukemia
    • Cellular Immunotherapy to Target EGFR for Glioblastoma
    • CGM-097
    • CLR-325
    • huCART19
    • IDH-305
    • IMP-701
    • LEQ-506
    • LGK-974
    • LML-134
    • LNA-043
    • LXH-254
    • LXS-196
    • MesoCART
    • NOV-10
    • NOV-11
    • NOV-7
    • NOV-8
    • NOV-9
    • octreotide acetate LAR
    • PBF-509
    • PCA-062
    • QCC-374
    • CART-123
    • Cellular Immunotherapy to Target B-Cell Maturation Factor for Multiple Myeloma
    • Antibody to Inhibit PD-L1 for Oncology
    • AUSRM-057
    • BLZ-945
    • BQS-481
    • BVB-808
    • Cellular Immunotherapy Program for Oncology
    • Cellular Immunotherapy to Target GD2 for Neuroblastoma
    • CHZ-868
    • cosyntropin ER
    • ESK-1
    • GNFPf-5069
    • Kartogenin
    • KR-22809
    • LCZ-960
    • LGB-321
    • LKZ-145
    • LQN-725
    • Monoclonal Antibody to Inhibit CXCR2 for Respiratory Diseases
    • NIBR-0213
    • NITD-349
    • NITD-916
    • NVPQBE-170
    • NVPTNKS-656
    • OXB-302
    • RP-6503
    • Small Molecule to Agonize GPR119 for Type 2 Diabetes
    • Small Molecule to Agonize GPR39 for Type 2 Diabetes
    • Small Molecule to Agonize Nurr1 for Multiple Sclerosis
    • Small Molecule to Inhibit LRRK2 for Parkinson's Disease
    • Small Molecule to Inhibit OX2R for Insomnia
    • Small Molecules to Antagonize VEGFR2 for Solid Tumors
    • Small Molecules to Inhibit Cytochrome bc1 Complex for Tuberculosis
    • Small Molecules to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes
    • Small Molecules to Inhibit Pan PI3K for Ovarian Cancer
    • Small Molecules to Inhibit Pan-RAF Kinase for Oncology
    • Small Molecules to Inhibit Renin for Hypertension
    • XOMA-089
    • ESBA-903 SR
    • LJH-685
  • Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology
  • Small Molecule to Agonize Adrenergic Beta-2 Receptor for COPD
  • Small Molecules for Tuberculosis
  • Small Molecules for Undisclosed Indication
  • Small Molecules to Antagonize NR2B for Depression
  • Small Molecules to Inhibit Acetyl-CoA Carboxylase for Metabolic, Cardiovascular and Infections
  • Small Molecules to Inhibit CFTR for Secretory Diarrhea
  • Small Molecules to Inhibit FPPS for Soft Tissue Cancer
  • Small Molecules to Inhibit PfATP4 for Malaria
  • Small Molecules to Inhibit PI4KIIIbeta for HCV
  • Novartis AG - Pipeline Analysis
  • Novartis AG - Pipeline Products by Target
  • Novartis AG - Pipeline Products by Route of Administration
  • Novartis AG - Pipeline Products by Molecule Type
  • Novartis AG - Pipeline Products by Mechanism of Action
  • Novartis AG - Recent Pipeline Updates
  • Novartis AG - Dormant Projects
  • Novartis AG - Discontinued Pipeline Products
  • Novartis AG - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Novartis AG - Company Statement
  • Novartis AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Novartis AG, Key Information
  • Novartis AG, Key Facts
  • Novartis AG - Pipeline by Indication, 2016
  • Novartis AG - Pipeline by Stage of Development, 2016
  • Novartis AG - Monotherapy Products in Pipeline, 2016
  • Novartis AG - Combination Treatment Modalities in Pipeline, 2016
  • Novartis AG - Partnered Products in Pipeline, 2016
  • Novartis AG - Partnered Products/ Combination Treatment Modalities, 2016
  • Novartis AG - Out-Licensed Products in Pipeline, 2016
  • Novartis AG - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Novartis AG - Pre-Registration, 2016
  • Novartis AG - Filing rejected/Withdrawn, 2016
  • Novartis AG - Phase III, 2016
  • Novartis AG - Phase II, 2016
  • Novartis AG - Phase I, 2016
  • Novartis AG - Phase 0, 2016
  • Novartis AG - Preclinical, 2016
  • Novartis AG - Discovery, 2016
  • Novartis AG - Pipeline by Target, 2016
  • Novartis AG - Pipeline by Route of Administration, 2016
  • Novartis AG - Pipeline by Molecule Type, 2016
  • Novartis AG - Pipeline Products by Mechanism of Action, 2016
  • Novartis AG - Recent Pipeline Updates, 2016
  • Novartis AG - Dormant Developmental Projects,2016
  • Novartis AG - Discontinued Pipeline Products, 2016
  • Novartis AG, Subsidiaries

List of Figures

  • Novartis AG - Pipeline by Top 10 Indication, 2016
  • Novartis AG - Pipeline by Stage of Development, 2016
  • Novartis AG - Monotherapy Products in Pipeline, 2016
  • Novartis AG - Combination Treatment Modalities in Pipeline, 2016
  • Novartis AG - Partnered Products in Pipeline, 2016
  • Novartis AG - Out-Licensed Products in Pipeline, 2016
  • Novartis AG - Pipeline by Top 10 Target, 2016
  • Novartis AG - Pipeline by Top 10 Route of Administration, 2016
  • Novartis AG - Pipeline by Top 10 Molecule Type, 2016
  • Novartis AG - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top